Taneptacogin alfa

Drug Profile

Taneptacogin alfa

Alternative Names: Active Site Inactivated Seven; Active Site Inhibited Seven; ASIS; FFR-FVIIa; FFR-VIIa

Latest Information Update: 07 Sep 2004

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class
  • Mechanism of Action Factor VIIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Coronary artery restenosis; Thrombosis; Vascular restenosis

Most Recent Events

  • 07 Sep 2004 Discontinued - Phase-II for Adult respiratory distress syndrome (unspecified route)
  • 06 Feb 2003 Phase-II clinical trials in Adult respiratory distress syndrome (unspecified route)
  • 21 Sep 2000 Discontinued-II for Coronary artery restenosis in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top